Abiopharma

We are translating our mRNA technology insights and learnings to create value in oncology, said Antony Blanc, Chief Business Officer and Chief Commercial Officer of CureVac. , a Belgium-based immunotherapy company, today announced that they have entered into a research and option agreement. Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies.